23ANDME HOLDING CO. -

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

15 сен 2024 02:00:00 Источник Nasdaq GlobeNewswire

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

15 сен 2024 02:00:00 Источник Nasdaq GlobeNewswire

One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations

12 сен 2024 15:05:00 Источник Nasdaq GlobeNewswire

23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024

03 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire

Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program

28 авг 2024 06:30:00 Источник Nasdaq GlobeNewswire

23andMe Reports First Quarter Fiscal 2025 Financial Results

08 авг 2024 15:05:01 Источник Nasdaq GlobeNewswire

23andMe Special Committee responds to CEO’s take-private proposal

02 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

23andMe Announces CEO’s Take-Private Proposal

01 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

23andMe to Report Q1 FY2025 Financial Results

25 июл 2024 15:45:00 Источник Nasdaq GlobeNewswire

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

25 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

28 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire

23andMe Launches New Genetic Report on Bipolar Disorder

05 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire

23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community

04 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

03 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history

29 май 2024 07:00:01 Источник Nasdaq GlobeNewswire

23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

23 май 2024 15:05:00 Источник Nasdaq GlobeNewswire

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

14 май 2024 06:00:00 Источник Nasdaq GlobeNewswire

23andMe to Report Q4 and Full Year FY2024 Financial Results

09 май 2024 15:50:07 Источник Nasdaq GlobeNewswire

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 15:05:00 Источник Nasdaq GlobeNewswire

23andMe announces CEO’s intention to pursue a potential take-private

18 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire